CN Patent

CN111747950B — 用于治疗癌症的嘧啶衍生物

Assigned to Shenzhen Forward Pharmaceuticals Co Ltd · Expires 2024-01-23 · 2y expired

What this patent protects

本文涉及用于治疗癌症的嘧啶衍生物。具体而言,本文涉及苯胺‑嘧啶化合物的制备方法和用途。本文涉及式(I)所示的苯胺基‑嘧啶化合物及其药学上可接受的盐,所述化合物或其盐可通过调节某些突变形式的表皮生长因子受体而用于治疗或预防疾病或病症。本文还涉及包含所述化合物或其盐的药物组合物,以及使用所述化合物及其盐治疗由EGFR或HER2或HER4所介导的多种疾病的方法。

USPTO Abstract

本文涉及用于治疗癌症的嘧啶衍生物。具体而言,本文涉及苯胺‑嘧啶化合物的制备方法和用途。本文涉及式(I)所示的苯胺基‑嘧啶化合物及其药学上可接受的盐,所述化合物或其盐可通过调节某些突变形式的表皮生长因子受体而用于治疗或预防疾病或病症。本文还涉及包含所述化合物或其盐的药物组合物,以及使用所述化合物及其盐治疗由EGFR或HER2或HER4所介导的多种疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111747950B
Jurisdiction
CN
Classification
Expires
2024-01-23
Drug substance claim
No
Drug product claim
No
Assignee
Shenzhen Forward Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.